menu
    • menu

    Company profile for Vasa Therapeutics

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Vasa Therapeutics, Inc. is a private, preclinical-stage biopharmaceutical company dedicated to the discovery and development of therapeutics targeting the pathophysiology of cardiovascular aging. The company operates in California and Poland, strategically positioned in dynamic academic and biotechnology innovation hubs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Vasa TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Suite 350 Encinitas, CA 92024
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://vasatherapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Vasa Therapeutics Presents at 36th Oppenheimer Life Sciences Conf
    Vasa Therapeutics Presents at 36th Oppenheimer Life Sciences Conf

    12 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vasa-therapeutics-announces-participation-at-the-36th-annual-oppenheimer-life-sciences-conference-302686822.html

    PR NEWSWIRE
    12 Feb 2026
    Share Share
    FDA Grants Vasa Fast Track for VS-041 in HFpEF
    FDA Grants Vasa Fast Track for VS-041 in HFpEF

    18 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vasa-therapeutics-granted-fda-fast-track-designation-for-vs-041-a-novel-investigational-treatment-of-heart-failure-with-preserved-ejection-fraction-hfpef-302618309.html

    PR NEWSWIRE
    18 Nov 2025
    Share Share
    Vasa Therapeutics Gains FDA Clearance For VS-041 Clinical Trial
    Vasa Therapeutics Gains FDA Clearance For VS-041 Clinical Trial

    14 Oct 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/drug-approval/vasa-therapeutics-secures-fda-ind-clearance-to-advance-vs-041-into-clinical-trial-for-hfpef-18009

    INDPHARMAPOST
    14 Oct 2025
    Share Share
    Vasa Therapeutics Advances Small Molecule VS-041 For HFpEF
    Vasa Therapeutics Advances Small Molecule VS-041 For HFpEF

    13 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vasa-therapeutics-receives-fda-ind-clearance-to-advance-novel-small-molecule-vs-041-for-the-treatment-of-heart-failure-with-preserved-ejection-fraction-hfpef-302581657.html

    PR NEWSWIRE
    13 Oct 2025
    Share Share
    Vasa Completes First-in-Human Study for Heart Failure Drug
    Vasa Completes First-in-Human Study for Heart Failure Drug

    04 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vasa-therapeutics-announces-successful-completion-of-first-in-human-study-for-investigational-therapy-vs-041-a-small-molecule-drug-candidate-for-heart-failure-with-preserved-ejection-fracture-302472610.html

    PR NEWSWIRE
    04 Jun 2025
    Share Share
    Quotient And Vasa Begin Human Trials Of VS-041 For Novel Heart Failure Therapy
    Quotient And Vasa Begin Human Trials Of VS-041 For Novel Heart Failure Therapy

    11 Sep 2024

    // PRESS RELEASE

    https://www.quotientsciences.com/news/quotient-sciences-and-vasa-therapeutics-announce-dosing-first-subjects-vs-041-novel-heart

    PRESS RELEASE
    11 Sep 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search